EndoTODAY | EndoATLAS | ¿Ü·¡¼³¸íÀÚ·á
±â»ýÃæ | ½Äµµ | À§ | À§¾Ï | ESD | õ±â´©¼³
Home | Guide | ÁÖÀÎÀå | ±¸µ¶ | °Ë»ö | ¸µÅ©
[ÀÏ¿ø³»½Ã°æ±³½Ç ¸ñ¿äÁ¡½ÉÁý´ãȸ 2016-4-28]
1. EGC (signet ring cell carcinoma, 1 cm)
¼ö¼úÀ» ÇÏ¿´°í 1 cm signet ring cell carcinoma¿´½À´Ï´Ù. Undifferentiated type histology¸¦ °¡Áø Á¶±âÀ§¾ÏÀ» ³»½Ã°æÀ¸·Î Ä¡·áÇصµ ÁÁÀ»Áö ³í¶õÀÌ °è¼ÓµÇ°í ÀÖ½À´Ï´Ù. ¾ÆÁ÷±îÁö´Â ¼ö¼úÀÌ Ç¥ÁØÀÔ´Ï´Ù. ±×·¯³ª ÀÛÀº undifferentiated type EGC, ƯÈ÷ 1 cm ¹Ì¸¸, ȤÀº 1.5 cm ¹Ì¸¸ signet ring cell carcinoma´Â ³»½Ã°æÀ¸·Î Ä¡·áÇغ¸´Ù´Â ÀÇ°ßÀÌ ÀÖ½À´Ï´Ù.
Àú´Â 2016³â À§¾ÏÇÐȸ¿¡¼ °ü·Ã ÀڷḦ ¹ßÇ¥ÇÑ ¹Ù ÀÖ½À´Ï´Ù (KINGCA 2016 ÀÌÁØÇà ±¸¿¬ ¹ßÇ¥). ½ÇÁ¦ ESD ¼ºÀûÀÌ ¾Æ´Ï¶ó ¼ö¼ú¹ÞÀº ȯÀÚÀÇ µ¥ÀÌŸ¸¦ ¹ÙÅÁÀ¸·Î ÇÑ simulationÀ̾ú½À´Ï´Ù.
The overall rate of curative resection for expanded indication undifferentiated type EGCs was only 42%. Especially, the curative resection rate in PD type EGCs was less than one third.
When we compare the characteristics between the curative resection lesions and non-curative resection lesions, there were no differences in terms of age, sex, location and gross type. However, the size in the curative resection group was smaller than the non-curative resection group. The size discrepancy between endoscopy size and pathology size was only 0.14 cm in curative resection group, but the size discrepancy was 1.5 cm in the non-curative resection group. This size discrepancy was one of the major reasons of non-curative resection.
This graph shows the reasons of non-curative resection in out ESD simulation. The most common reason was the size larger than 2 cm, followed by SM invasion and LV invasion.
There were three cases with lymph node metastasis in the curative resection group. Two were PD-type and one was SRC-type in the forceps biopsy. In the final surgical pathology, they was PD type mucosal cancers with SRC components larger than 1.0 cm.
Because the size was the most common reason of non-curative resection, we modified the expanded indication criteria into 1.5 cm, 1 cm and 0.6 cm. When a size criterion of 1 cm was applied, the number of ESD candidates were decreased by 51.4% and the curative resection rate was increased into 54%. However, this increase in the curative resection rate was mostly seen in the SRC type EGCS. The curative resection rate in PD type was almost the same in the smaller lesions.
Undifferentiated type EGCÀÇ ³»½Ã°æÄ¡·á¿¡ ´ëÇÑ 2016³â 5¿ù Á¦ ÀÔÀåÀº ´ÙÀ½°ú °°½À´Ï´Ù.
(1) Poorly differentiated adenocarcinoma¿Í signet ring cell carcinoma´Â »ó´çÈ÷ ´Ù¸£´Ù.
(2) 1 cm ÀÌÇÏ flatÇÑ signet ring cell carcinoma¿¡¼ ½Ã¼úÀ» °í·ÁÇÒ ¼ö ÀÖ´Ù.
(3) Undifferentiated type EGC¿¡ ´ëÇÑ ³»½Ã°æÄ¡·á´Â ¾ÆÁ÷ Ç¥ÁØÄ¡·á¶ó°í ºÎ¸¦ ¼ö ¾ø´Ù. ȯÀÚ¿¡°Ô ¸ÕÀú ³»½Ã°æÄ¡·á¸¦ ±ÇÇÒ ´Ü°è´Â ¾Æ´Ï´Ù. ¸¸¾à ȯÀÚ°¡ ³»½Ã°æ Ä¡·á¸¦ ¿äûÇÏ´Â °æ¿ì¿¡´Â ¾ÆÁ÷ investigational approach¶ó´Â Á¡À» ȯÀÚ¿¡°Ô ¸í¹éÈ÷ ¼³¸íÇÑ ÈÄ Ä¡·á¹æħÀ» °áÁ¤ÇÑ´Ù.
¼Òȼº±Ë¾çÀ̾ú½À´Ï´Ù. Á¦±ÕÄ¡·á¸¦ ÇÏ¿´½À´Ï´Ù. ±×·±µ¥ ȯÀÚ°¡ ÃßÀû°Ë»ç¸¦ ¹ÞÀ¸·¯ ¿À½ÃÁö ¾Ê¾Ò½À´Ï´Ù. Á¦±ÕÀÌ Àß µÇ¾ú´ÂÁö È®ÀεÇÁö ¾ÊÀº »óÅ¿´½À´Ï´Ù. ±×·±µ¥ ¾î´À ³¯ ȯÀÚ°¡ ±Þ¼º º¹ÅëÀ¸·Î ÀÀ±Þ½ÇÀ» ¹æ¹®ÇÏ¿´½À´Ï´Ù. ¼Òȼº ±Ë¾ç õ°øÀ̾ú°í ¼ö¼úÀ» ¹Þ¾Ò½À´Ï´Ù.
¿Ü·¡¿¡¼ ÃßÀû°Ë»ç¸¦ ±ÇÇÑ È¯ÀÚ Áß ÀϺδ º´¿øÀ» ãÁö ¾Ê½À´Ï´Ù. Follow up lossµÈ ȯÀÚ ¸ðµÎ¿¡°Ô ¿¬¶ôÀ» ÃëÇÏ¿© Àç°ËÀ» ±ÇÇÏ´Â °ÍÀº ½¬¿î ÀÏÀÌ ¾Æ´Õ´Ï´Ù. ¿ÇÀº ÀÏÀÎÁöµµ ¸ð¸£°Ú½À´Ï´Ù. 'ÃßõÇÑ ³¯¿¡ ȯÀÚ°¡ ¿À½ÃÁö ¾ÊÀ¸¸é ÀüÈ·Î ¿¬¶ôÇÏ°Ú´Ù'°í µ¿ÀǸ¦ ¹ÞÀº °Íµµ ¾Æ´Ï±â ¶§¹®ÀÔ´Ï´Ù.
ȯÀÚ¿¡°Ô ÃæºÐÈ÷ ¼³¸íÇÒ ½Ã°£À» ¸¶·ÃÇÏÁö ¾ÊÀº ´ëÇѹα¹ ÀÇ·á´Â ¹«Ã´ ÈÄÁø ½Ã½ºÅÛÀÔ´Ï´Ù. ½Î°í ÈÄÁý´Ï´Ù.
3. Total gastrectomy ÈÄ anastomosis site Á÷ÇϹæ Àç¹ß
À§¾Ï ¼ö¼ú 10°³¿ù ÈÄ dysphagia·Î ³»¿øÇϽŠºÐ¿¡¼ ¹ß°ßµÈ anastomosis site Á÷ÇϹæ Àç¹ßÀÔ´Ï´Ù. ÀÌ È¯ÀÚ´Â anastomosis site ÇϹæÀ̹ǷΠbenign stricture´Â ¾Æ´Ï¶ó´Â °ÍÀ» ½±°Ô ¾Ë ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª °æ¿ì¿¡ µû¶ó¼´Â anastomosis site recur¿Í ±¹¼ÒÀç¹ßÀÇ ±¸ºÐÀº ½±Áö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù. º¸Åë 7-8°³¿ù ÀÌÀü¿¡ ¹ß»ýÇϸé benign stricture°¡ ¸¹°í ±× ÀÌÈÄ´Â ¾Ï Àç¹ßÀÌ ¸¹½À´Ï´Ù. ¿¹Àü ÀڷḦ ¿Å±é´Ï´Ù.
À§¾Ï ¼ö¼ú ÈÄ ¹®ÇպΠÇùÂøÀÌ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ƯÈ÷ total gastrectomy ÈÄ ½Äµµ¿Í ¼ÒÀåÀÇ ¿¬°áºÎ°¡ membraneousÇÏ°Ô Á¼¾ÆÁö´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ÃÖ±Ù¿¡´Â ¸¹ÀÌ ÁÙ¾úÁö¸¸ 2005³â¿¡ ¹ßÇ¥µÈ »ï¼º¼¿ïº´¿øÀÇ ÀÚ·á(Lee SY, Lee JH et al. EJSO 2005;31:265-269 )¸¦ º¸¸é total gastrectomyÈÄ 8-9% ÀüÈÄ¿¡¼ stricture°¡ ¹ß»ýÇÏ¿´½À´Ï´Ù.
¼ö¼úÇÑ È¯ÀÚ¿¡°Ô ¹Ì¸® obstruction Áõ»óÀ» ¼³¸íÇØ ÁÖ´Â °ÍÀº ¸Å¿ì Áß¿äÇÕ´Ï´Ù. °£È¤ obstruction Áõ»óÀ» ¼ö¼ú ÈÄ ´ç¿¬È÷ ¹ß»ýÇÒ ¼ö ÀÖ´Â º¯È·Î »ý°¢ÇÏ¿© ¸î ´ÞÀ̳ª Âü°í Áö³»´Â ȯÀÚµéÀ» ¸¸³¯ ¼ö ÀÖ½À´Ï´Ù.
Anastomosis siteÀÇ benign postoperative stricture°¡ ÈçÇÏÁö¸¸ µå¹°°Ô local recurrenceµµ °¡´ÉÇÕ´Ï´Ù. Benign stricture´Â ¼ö¼ú Á÷ÈĺÎÅÍ ¼ö°³¿ù À̳»¿¡ È£¹ßÇÏ°í 1³â ÀÌÈÄ¿¡ ¹ß»ýµÇ´Â °æ¿ì´Â µå¹´´Ï´Ù. ¹Ý¸é À§¾ÏÀÇ local recurrence¿¡ ÀÇÇÑ stricture´Â À§¾Ï ¼ö¼ú ¹Ý³â °æºÎÅÍ 2-3³â »çÀÌ¿¡ ¹ß°ßµÇ´Â °æÇâÀÌ ÀÖ½À´Ï´Ù. ÀÏÂï ¹ß°ßµÇ¸é benign, ´Ê°Ô ¹ß°ßµÇ¸é malignancy¶ó´Â °æÇâÀÔ´Ï´Ù.
¹®ÇպΠÁÖÀ§ÀÇ Àç¹ßÀº ¹®ÇպΠ¼Ò¸¸Ãø¿¡ ¸¹À¸¸ç, ¹®ÇպΠÁÖÀ§ Á¡¸·ÀÇ °áÀý»ó À¶±â³ª Á¡¸· ºñÈÄ·Î ³ªÅ¸³¯ ¼ö ÀÖ½À´Ï´Ù. ¼ö¼ú ÈÄ¿¡´Â ¹®ÇÕ ºÎÀ§ÀÇ ºÎÁ¾°ú ¹ßÀû, ÀÜÁ¸ÇÏ´Â ºÀÇÕ»ç ÁÖº¯À¸·Î ¿°Áõ ¹× ºÎºÐÀûÀÎ ±Ë¾ç µîÀº ÀÜÀ§¾Ï ¶Ç´Â ¾ÏÀÇ Àç¹ß°ú È¥µ·µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÚ¼¼È÷ °üÂûµÇ°í Á¶±ÝÀÌ¶óµµ ÀÌ»óÇϸé Á¶Á÷°Ë»ç¸¦ ÇÏ´Â ¼ö ¹Û¿¡ ¾ø½À´Ï´Ù. ¾Æ·¡´Â ¼ö³â Àü »ï¼º¼¿ïº´¿øÀÇ ³í¹®(Lee SY, Lee JH et al. EJSO 2005;31:265-269) ¿¡ ½Ç·È´ø Àç¹ß¿¹µéÀÔ´Ï´Ù.
Benign post-op stricture´Â ¼ö¼ú ÈÄ 4-8°³¿ù¿¡ ¹ß»ýÇÕ´Ï´Ù. 1³â ÀÌÈÄ¿¡ ¹ß°ßµÈ ÇùÂøÀº ´ëºÎºÐ ±¹¼ÒÀç¹ßÀÔ´Ï´Ù. µû¶ó¼ total gastrectomyÈÄ anastomosis site stenosis·Î ³»¿øÇÑ È¯ÀÚ¿¡¼ °¡Àå ¸ÕÀú È®ÀÎÇÒ °ÍÀº ¼ö¼ú ½ÃÁ¡ÀÔ´Ï´Ù. ¼ö¼úÇÑÁö 1³â ÀÌ»ó °æ°úÇÏ¿´À¸¸é ´ëºÎºÐ local recurÀÔ´Ï´Ù. °Ô´Ù°¡ ¼ö¼ú ´ç½Ã º´±â°¡ ³ô¾Ò´Ù¸é °ÅÀÇ Æ²¸²¾ø½À´Ï´Ù. ±×·¯³ª ¿ªÀº ¼º¸³ÇÏÁö ¾Ê½À´Ï´Ù. 1³â ¹Ì¸¸À̶ó°í ¸ðµÎ benign post-op stenosisÀÎ °ÍÀº ¾Æ´Õ´Ï´Ù. Á¶±ÝÀ̶ó°í Àǽɽº·¯¿ì¸é ¹Ù·Î dilatationÀ» ÇÒ °ÍÀÌ ¾Æ´Ï°í Á¶Á÷°Ë»ç¸¦ ÇØ¾ß ÇÕ´Ï´Ù.
* Âü°í: EndoTODAY À§¾Ï ¼ö¼ú ÈÄ ¼Ò°ß
4. »óºÎ³»½Ã°æ¿¡¼ ¹ß°ßµÈ ampulla of Vater adenoma
5. Ovary cancer recur at colon
Ovary cancer ¼ö¼ú ÈÄ CT¿¡¼ rectosigmoid junction ºÎÀ§°¡ µÎ²¨¿ö ½ÃÇàÇÑ ´ëÀå³»½Ã°æÀÔ´Ï´Ù. Á¶Á÷°Ë»ç´Â metastatic serous carcinoma°¡ ³ª¿Ô½À´Ï´Ù.
1) SMC Endoscopy Unit »ï¼º¼¿ïº´¿ø ³»½Ã°æ½Ç
2) SMC Monday GI conference »ï¼º¼¿ïº´¿ø ÀÏ¿ø³»½Ã°æ±³½Ç ¿ù¿äÁ¡½É¼ÒȱâÁý´ãȸ
3) SMC Thursday endoscopy conference »ï¼º¼¿ïº´¿ø ÀÏ¿ø³»½Ã°æ±³½Ç ¸ñ¿äÁ¡½É³»½Ã°æÁý´ãȸ
© EndoTODAY Endoscopy Learninng Center. Jun Haeng Lee.